Garrison et al., developed the Senti-202, a CAR-NK cell product expressing simultaneously an activating CAR targeting CD33 and/or FLT3 on AML cells, an inhibitory anti-endomucin (EMCN) CAR that protects EMCN+ hematopoietic cells, and IL15 [69]. Here, CD33 is linked to acute myeloid leukemia.